Advanced Enzyme Technologies Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 357.1 as of 05 May 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 49.4 on March 2021 to 38.1 on March 2025 . This represents a CAGR of -5.06% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 143384 crore on March 2021 to ₹ 416392 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 191.66 crore as compare to the Sep '25 revenue of ₹ 194.81 crore. This represent the decline of -1.62% The revenue of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 16099 crore as compare to the Sep '25 revenue of ₹ 14948 crore. This represent the growth of 7.7% The ebitda of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 69.07 crore as compare to the Sep '25 ebitda of ₹ 70.34 crore. This represent the decline of -1.81% The ebitda of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 5037 crore as compare to the Sep '25 ebitda of ₹ 4996 crore. This represent the growth of 0.82% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 43.18 crore over 7 quarters. This represents a CAGR of 12.79% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 3401 crore over 7 quarters. This represents a CAGR of 10.16% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,959 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 437,662 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Sun Pharmaceutical Industries Ltd?

As of May 5, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹353.8. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1824.1.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.